Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2006

View Archived Issues

Nostrum obtains rights to clot busting therapeutic protein from IMTECH

AstraZeneca gives lowdown on second quarter

Gardant updates acquisition and spin-off details

Pozen and AstraZeneca to develop esomeprazole/naproxen fixed dose combinations

Preterm birth prevention study of Prochieve completes enrollment

Phase II study of IR-103 in HIV patients cleared to add French sites

Oncaspar in combination with Gemzar begins phase I study

Enzon's IND approved for recombinant human mannose-binding lectin

Phase IIb study to assess PEP-005 Topical in actinic keratosis

Archemix and Nuvelo expand aptamer collaboration

CHDI and Edison team up to develop therapeutics for Huntington's disease

Satraplatin studied with Tarceva in phase II NSCLC trial

In vivo data show antiviral activity of AC-03-636

Phase IIb stroke study of DP-b99 completes enrollment

Alzheimer's candidate AZD-103 cleared for phase I study

BTA-798 for human rhinovirus advances through phase I testing

VAS-2870: novel NOX inhibitor for cardiovascular disease

Alemtuzumab to be tested in new phase II study for T-cell large granular lymphocytic leukemia

SAHA shows promise for the treatment of SMA

Positive phase I results of CI-1033 in combination with docetaxel in solid tumors reported

Novel antiviral agents reported in recent Shionogi patent

New analgesic agents reported in recent Schwarz patent

Recent patents cover novel BACE inhibitors for Alzheimer's disease

Recent patents describe new agents for anxiety, sleep disorders, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...